Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852303 | 1.00 | TLR7 (0.60) | TLR7 | |
| SCHEMBL4335778 | 0.85 | TLR7 (0.59) | TLR7 | |
| SCHEMBL6031026 | 0.85 | TLR7 (0.57) | TLR7 | |
| SCHEMBL4336407 | 0.84 | TLR7 (0.55) | TLR7 | |
| SCHEMBL5617019 | 0.84 | TLR7 (0.60) | TLR7 | |
| SCHEMBL4331154 | 0.83 | TLR7 (0.56) | TLR7 | |
| SCHEMBL893544 | 0.82 | TLR7 (0.53) | TLR7 | |
| SCHEMBL30200834 | 0.82 | TLR7 (0.53) | TLR7 | |
| SCHEMBL5616920 | 0.82 | TLR7 (0.62) | TLR7 | |
| SCHEMBL31006041 | 0.81 | TLR8 (0.55) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343784-B1 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS and pharmaceutical compositions comprising the same. | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-08 | — | — | EP | claimed |
| US-20040077678-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-22 | — | — | US | claimed |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | claimed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | claimed |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | THE UNIVERSITY OF CHICAGO | 2025-02-06 | — | — | US | disclosed |
| EP-4166572-A1 | ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF | Rinat Neuroscience Corp. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20230073245-A1 | TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND METHODS OF USE | THE UNIVERSITY OF CHICAGO (US) | 2023-03-09 | — | — | US | disclosed |
| EP-3230319-B1 | ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF | RINAT NEUROSCIENCE CORP (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11338035-B2 | Anti-PD-1 antibodies and methods of use thereof | RINAT NEUROSCIENCE CORP. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-107746852-B | Prostate-associated antigens and vaccine-based immunotherapeutic therapies | 辉瑞公司 | 2021-10-08 | — | — | CN | disclosed |
| US-11110158-B2 | Prostate-associated antigens and vaccine-based immunotherapy regimens | PFIZER INC. (US) | 2021-09-07 | — | — | US | disclosed |
| CN-107207593-B | anti-PD-1 antibodies and methods of use thereof | 雷纳神经科学公司 | 2021-06-22 | — | — | CN | disclosed |
| US-20040077678-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-6660735-B2 | Inducing cytokine biosynthesis; viral diseases, neoplastic disorders | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-6656938-B2 | Inducing cytokine biosynthesis in animals, for the treatment of diseases, including viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-02 | — | — | US | disclosed |
| EP-1343784-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M Innovative Properties Company (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-21 | — | — | US | disclosed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2002046191-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230073245-A1 | TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND METHODS OF USE | TLR3, TLR9, TLR1 | TLR7 4/4885 |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885 |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885 |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | NFKBIA, NFRKB, NFKB2 | TLR7 20/4885 |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885 |
| US-20040077678-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.